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Primary pulmonary diffuse large B cell lymphoma (PPDLBCL) is extremely rare, let alone coexistence of it
with other tumors. Misdiagnosis might be made if this unique situation failed to be considered. Herein,
we report a case of collision tumor made up of PPDLBCL and lung adenocarcinoma that we treated and
followed for three years. After surgery to remove the tumor, the patient received chemotherapy used
clinically for PPDLBCL and lung adenocarcinoma and completely recovered. Regular review did not
observe recurrence. The mechanism of collision tumor in this case is unclear and the tumor was non-
immunoreactive for Napsin A and ALK, which is consistent with former reports. In conclusion, this report
showed a rare collision tumor composed by PPDLBCL and lung adenocarcinoma and introduced the
successful treatment regimen for it.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
PPDLBCL is a kind of non-Hodgkin lymphomas arising from lung
tissue. It is extremely rare and observed only in 10% cases of pri-
mary pulmonary non-Hodgkin lymphoma1,2. Because of nonspe-
ciﬁc clinical symptoms, it might be misdiagnosed as infection,
tuberculosis or even lung cancer. The criteria for the diagnosis of
PPDLBCL include the following: pathological and immunohisto-
chemical features of DLBCL, a primary lesion restricted to the lung
with or without minimal hilar lymph node involvement, and clin-
ical, radiological, and pathological exclusion of the disease at
distant sites3,4. A few cases of PPDLBLwere reported in recent years.
While, when it met diagnostic criteria of PPDLBCL, diagnosis of
PPDLBCL should not be made immediately. An extremely unique
situation must be considered and it is coexistence of PPDLBCL with
other cancers, including lung cancers and cancers transferred to
lungs, such as breast cancer. Tissue samples should be took at
different parts of tumors to achieve precise diagnosis. Only by do-
ing this, suitable treatment regime can be chosen.cer Center, Cancer Center and
spital of Sichuan University,
tric Emergency & Critical Care Med
es/by-nc-nd/4.0/).In this report, we described a female patient whowas diagnosed
as PPDLBCL and lung adenocarcinoma. Two different malignant
tumor cells were found at the same mass. Chemotherapy regime
used clinically for treatment of lung adenocarcinoma and DLBCL
was used. After treatment, the patient was completely recovered
and kept healthy for 3 years till present.
2. Case report
A 60-year-old female patient presented with left chest pain
came for our help in January, 2013. She had no fever, night sweats,
chills and chronic cough and was a nonsmoker. The physical ex-
amination did not reveal any signiﬁcant abnormalities. CT scan
showed a 6.0 cm  4.0 cm  2.0 cm upper left chest wall mass
(Fig. 1). Needle biopsy through the chest wall revealed a adeno-
carcinoma of lung. No metastasis was discovered. As there were no
surgical contraindications, the patient thenwas admitted to clinical
thoraco-surgery to remove the tumor. Immunohistochemical assay
revealed both a lung adenocarcinoma and a large B cell-type lym-
phoma (DLBCL). The tumor was immunoreactive for Vim, CD20,
CD79a and CD45 (partly), and nonimmunoreactive for NapsinA, S-
100 and ALK (Fig. 2). Both lung adenocarcinoma cells and B cell
lymphoma cells were surrounded by inﬂammation cells (Fig. 3).
She completed 4 cycles of chemotherapy with gemcitabine,
cisplatin (GP) regimen and 2 cycles with cyclophosphamide,icine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
Fig. 1. Thoracic CT scan. aeb. Before surgery, a tumor can be observed at upper left chest wall, ced. Review of the third year, tumor is removed and no recurrence is observed.
Fig. 2. Surgical biopsy of collision tumor. a. Lung adenocarcinoma (H&E staining), b. Diffuse large B cell lymphoma (H&E staining), c. Immunohistochemical assay revealed positive
of CD20(c).
Fig. 3. Malignant tumor cells are surrounded by inﬂammation cells. a. Inﬂammation cells locate around lung adenocarcinoma cells, b. B cell lymphoma cells are surrounded by
inﬂammation cells.
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tion of chest CT showed themass was disappear (Fig. 1). The patient
kept healthy without tumor recurrence ever after.
3. Discussion
The simultaneous occurrence of two histological distinct tumors
at the same site might be caused by different biologic reasons. In
some cases, variable tumorsmay develop simultaneously as a result
of a pure coincidence which was called “collision tumors”5. In fact,
in addition to the same site, collision tumors can also occur within
adjacent organs or in conjunctionwith a systemic malignancy or as
a metastatic phenomenon3. The mechanisms for collision tumors
were still unclear and two of them have been proposed, including
(1) alteration of regional microenvironment by an already present
tumor, which lead to increased risk of developing the other tumor.
For example, accumulation of large number of inﬂammation cells
caused by existence of one cancer can promote cell proliferation,
which is an important pathogenesis of malignant tumors. (2) Two
malignant cells in collision tumor originated from carcinogenesis of
a common stem cell5. In this case, the possibility of lung adeno-
carcinoma and DLBCL coming from the same stem cell was small as
the two kinds of tumor cells originated totally from different pro-
genitor cells. The mechanism driving this collision tumor more
inclined to the change of local microenvironment caused by one
tumor, leading to developing of another one. While, which one
appeared earlier was unclear. It is well known that a gene mutation
can lead to several tumors, such as RAS gene mutation, which will
cause pancreatic cancers or colorectal cancers. Collision tumors
may also be a result of a genemutation, but evidence can prove this
guess is notmuch. In one case, the authors reported that they found
over-expression of IL-17A and CD70 gene in a collision tumor made
up of primary laryngeal mucosal melanoma and invasive squamous
cell carcinoma6.
In the present case, lung adenocarcinoma and DLBCL were
discovered at the samemass located in left lung. It is the ﬁrst report
of such unique collision tumor, to our knowledge. The tumor stains
for CD20 and CD79a, which are markers of B-lineage. While, Napsin
A, frequently used to classify a tumor of unknown origin as lung
primary, is lack of staining. It was reported that anaplastic lym-
phoma kinase-positive diffuse large B cell lymphoma (ALK-DLBCL)
was positive in expressing Napsin A7. Our result of ALK wasnegative, which was a supplement for the former report. We guess
that Napsin A might be used as a new marker for ALK-DLBCL.
Testing of ALK is relatively expensive and replacing it with Napsin
Awould reduce the payment. While, the guess need to be furtherly
studied.
There is no standard chemotherapy choice after operation
because no such cases had been reported before. We designed
therapeutic scheme according to the character of the neoplasm.
Considering the collision tumor was made up with lung adeno-
carcinoma and DLBCL, GP regime was utilized for 4 cycles of
chemotherapy, which is effective for both lung adenocarcinoma
and lymphoma. Clinically, DLBCL needs 6 cycles of chemotherapy,
so CHOP regime, which is the ﬁst choice of DLBCL, was added to
meet the dose requirement and used for another 2 cycles. After
surgery and chemotherapy, the patient is completely recovered. No
recurrence was observed by regular review for 3 years. The suc-
cessful treatment of the patient provides us with a therapeutic
scheme for reference.
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